









市場行情
/
股票
/
nasdaq-aytu
/

Aytu Biopharma Inc

AYTU

2.550USD

+0.080+3.24%

收盤 12/19, 16:00（美東）報價延遲15分鐘

25.28M總市值

虧損本益比TTM



Aytu Biopharma Inc

2.550

+0.080+3.24%

概覽公司財務分析

概覽

公司

財務

分析

關於 Aytu Biopharma Inc 公司

Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.

Aytu Biopharma Inc簡介



公司代碼AYTU

公司名稱Aytu Biopharma Inc

上市日期Oct 20, 2017

CEODisbrow (Joshua R)

員工數量82

證券類型Ordinary Share

年結日Oct 20

公司地址7900 E. Union Avenue

城市DENVER

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編80237

電話17204376580

網址https://aytubio.com/

公司代碼AYTU

上市日期Oct 20, 2017

CEODisbrow (Joshua R)

Aytu Biopharma Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Jarrett T. (Josh) Disbrow

Chief Business Officer

61.57K

+108.97%

Mr. Ryan J. Selhorn, CPA

Chief Financial Officer, Treasurer, Corporate Secretary

49.74K

+210.89%

Mr. Greg Pyszczymuka

Chief Commercial Officer

36.10K

+51.62%

Mr. Carl C. Dockery

Independent Director

21.15K

+89.67%

Ms. Vivian H. Liu

Independent Director

19.82K

+101.78%

Mr. Abhinav (Abi) Jian

Independent Director

Mr. John A. Donofrio, Jr.

Independent Chairman of the Board

Mr. Joshua R. (Josh) Disbrow

Chief Executive Officer, Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Jarrett T. (Josh) Disbrow

Chief Business Officer

61.57K

+108.97%

Mr. Ryan J. Selhorn, CPA

Chief Financial Officer, Treasurer, Corporate Secretary

49.74K

+210.89%

Mr. Greg Pyszczymuka

Chief Commercial Officer

36.10K

+51.62%

Mr. Carl C. Dockery

Independent Director

21.15K

+89.67%

Ms. Vivian H. Liu

Independent Director

19.82K

+101.78%

Mr. Abhinav (Abi) Jian

Independent Director

收入明細

單位: USD更新時間: 10月6日週一

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

ADHD portfolio

57.58M

86.73%

Pediatric portfolio

8.77M

13.21%

Other

37.00K

0.06%

由於公司未披露，未能獲取相關數據

業務

地區

業務USD

名稱

營收

佔比

ADHD portfolio

57.58M

86.73%

Pediatric portfolio

8.77M

13.21%

Other

37.00K

0.06%

股東統計

更新時間: 12月17日週三

持股股東

股東類型

持股股東

佔比

Nantahala Capital Management, LLC

10.67%

Stonepine Capital Management, LLC

8.75%

AWM Investment Company, Inc.

6.08%

The Vanguard Group, Inc.

2.73%

Diadema Partners LP

2.68%

其他

69.09%

持股股東

佔比

Nantahala Capital Management, LLC

10.67%

Stonepine Capital Management, LLC

8.75%

AWM Investment Company, Inc.

6.08%

The Vanguard Group, Inc.

2.73%

Diadema Partners LP

2.68%

其他

69.09%

股東類型

持股股東

佔比

Hedge Fund

16.00%

Investment Advisor/Hedge Fund

15.97%

Individual Investor

5.41%

Investment Advisor

3.17%

Bank and Trust

0.03%

其他

59.43%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

3.62M

34.64%

2025Q3

3.62M

35.61%

+200.00K

2025Q2

3.42M

23.61%

+1.37M

2025Q1

1.88M

32.85%

-147.25K

2024Q4

1.88M

35.64%

-167.56K

2024Q3

2.05M

38.87%

-5.48K

2024Q2

2.06M

35.52%

+258.31K

2024Q1

1.80M

39.85%

-420.62K

2023Q4

1.77M

40.04%

+44.24K

2023Q3

1.73M

39.72%

+20.75K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Nantahala Capital Management, LLC

1.09M

10.96%

Jun 30, 2025

Stonepine Capital Management, LLC

812.68K

8.2%

+348.95K

+75.25%

Jun 30, 2025

AWM Investment Company, Inc.

619.87K

6.25%

+619.87K

Jun 30, 2025

The Vanguard Group, Inc.

27.89K

0.28%

Jun 30, 2025

Disbrow (Joshua R.)

153.26K

1.71%

+66.67K

+76.99%

Jun 09, 2025

Lytton (Laurence W)

506.61K

5.11%

+506.61K

Jun 09, 2025

Two Sigma Investments, LP

35.03K

0.35%

+35.03K

Jun 30, 2025

Renaissance Technologies LLC

89.91K

0.91%

+13.09K

+17.04%

Jun 30, 2025

Geode Capital Management, L.L.C.

53.87K

0.54%

-75.00

-0.14%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Dimensional US Core Equity 1 ETF

DFA Dimensional US Sustainability Core 1 ETF

Dimensional US Core Equity 1 ETF

佔比0%

DFA Dimensional US Sustainability Core 1 ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Jan 05, 2023

Merger

20→1

Jan 05, 2023

Merger

20→1

Jan 05, 2023

Merger

20→1

Jan 05, 2023

Merger

20→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

公告日期

類型

比率

Jan 05, 2023

Merger

20→1

Jan 05, 2023

Merger

20→1

Jan 05, 2023

Merger

20→1

Jan 05, 2023

Merger

20→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

常見問題

Aytu Biopharma Inc的前五大股東是誰？



Aytu Biopharma Inc的前五大股東如下：
Nantahala Capital Management, LLC
持有股份：1.09M
佔總股份比例：10.96%。
Stonepine Capital Management, LLC
持有股份：812.68K
佔總股份比例：8.20%。
AWM Investment Company, Inc.
持有股份：619.87K
佔總股份比例：6.25%。
The Vanguard Group, Inc.
持有股份：27.89K
佔總股份比例：0.28%。
Disbrow (Joshua R.)
持有股份：153.26K
佔總股份比例：1.71%。